首页> 外国专利> PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11 (PTPN11) AND TRIPLE-NEGATIVE BREAST CANCER

PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11 (PTPN11) AND TRIPLE-NEGATIVE BREAST CANCER

机译:蛋白酪氨酸磷酸酶,非受体11型(PTPN11)和三阴性乳腺癌

摘要

The present invention relates to a method for treating breast cancer in a subject having a breast cancer of the triple-negative type, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2). The present invention also relates to a method for treating breast cancer in a subject having a breast cancer over-expressing the “SHP2 signature” genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2), wherein said “SHP2 signature” genes consist of the genes SGCB, ZSCAN12, ID4, ZIC3, CPVL, HLA-A, MCOLN3, SPATA18, TMEM45A, GNAL, CYBRD1, TSPAN7, ZEB1, CNTLN, NEFL, CENPV, ARL6, HPRT1, LRRC34, PDPN, BEND7, SLC16A10, FAM27E1, PLEKHA1, HERC5, CHIC1, PHF6, ELOVL4, ANTXR1, PRAME, SCML1, CLIP4, CECR2, CNOT10, IGF2BP3, NAP1L3, GPC3, KIAA1804, DGKE, FAS, EPHA6, KDELC1, CRISPLD1, DOCK3, ACSL4, CNTNAP3, PLEKHM3, RDX, TBX18, RRAGD, HOXB5, SNCA, FUNDC2, ITGA8, HFM1, IGF2BP2, CCND2, SGTB, MKX, CRYBG3, WBP5, LPHN3, BEX4, CPNE8, GLDC, SLC35F1, HOXA13, SERPINF1, NEFM, SYCP2L, FHL1, APOBEC3C, CALD1, FKBP10, HOXD11, DENND2C, LRRC49, FAM55C, KIAA0408, HOXB9, C160RF62, ACN9, TUSC3, ELOVL2, SPOCK3, HOXB6, WDR35, MPP1, FBX038, PRKAA2, SLAIN1, NPHP3, KIAA1524, PRPS1, GJC1, AMOT, SLC9A6, KCTD12, NUP62CL, DZIP3, JAM3, HOXA9, ANKRD19, CDKN2A, BCAT1, OAT, LPHN2, CCDC82, HSD17B11, SAMHD1, WDR17, STK33, GSTP1, TRPC1, CKB, LIN28B, ALDH1L2, SACS, CLGN, MY03A, EPB41L3, SLC25A27, VCAN, GPX8, GALNT13, PVRL3, MOXD1, HEY1, MAP7D3, ESD, MPP6, EYA4, SPG20, ZDBF2, ZNF204, IFT57, AKR1B1, ADAT2, ZNF717, CCDC88A, ZNF215, MIDI, FBN2, LOC100130876, TCEAL8, IGF2BP1, ANKRD18B, PLAGL1, PM20D2, LDHB, C150RF51, PTPN11, EPB41L2, TLE4, GOLM1, C60RF192, HOXD13, SLIT2, UCHL1, DYNC2H1, CPS1, GPR180, PYGL, NRN1, PRTFDC1, SLC16A1, DSC3, TMC01, LRCH2, SLC6A15, DZIP1, HOXA5, HSPA4L, CDR1, PLS3, ECHDC1, SMARCA1, CXORF57, HOXD10, and IRS4.
机译:本发明涉及一种在患有三阴性类型乳腺癌的受试者中治疗乳腺癌的方法,该方法包括向所述受试者施用治疗有效量的蛋白酪氨酸磷酸酶调节剂的步骤,受体11型(PTPN11)基因或其基因产物(Shp2)。本发明还涉及一种与正常乳腺组织样品相比,在患有过度表达“ SHP2签名”基因的乳腺癌的受试者中治疗乳腺癌的方法,该方法包括对所述受试者给予治疗有效的步骤。量的蛋白质酪氨酸磷酸酶,非受体11型(PTPN11)基因或其基因产物(Shp2)的调节剂,其中所述“ SHP2签名”基因由基因SGCB,ZSCAN12,ID4,ZIC3,CPVL,HLA组成-A,MCOLN3,SPATA18,TMEM45A,GNAL,CYBRD1,TSPAN7,ZEB1,CNTLN,NEFL,CENPV,ARL6,HPRT1,LRRC34,PDPN,BEND7,SLC16A10,FAM27E1,PLEKHA1,HERC5,CHIC1,PHF6TX,ELO ,SCML1,CLIP4,CECR2,CNOT10,IGF2BP3,NAP1L3,GPC3,KIAA1804,DGKE,FAS,EPHA6,KDELC1,CRISPLD1,DOCK3,ACSL4,CNTNAP3,PLEKHM3,RDX,TBX18,FRAGD,HOXB5C,SN5, ,IGF2BP2,CCND2,SGTB,MKX,CRYBG3,WBP5,LPHN3,BEX4,CPNE8,GLDC,SLC35F1,HOXA13,SERPINF1,NEFM,SYCP2L,FHL1,APOBEC3C,C ALD1,FKBP10,HOXD11,DENND2C,LRRC49,FAM55C,KIAA0408,HOXB9,C160RF62,ACN9,TUSC3,ELOVL2,SPOCK3,HOXB6,WDR35,MPP1,FBX038,PRKAA2,SLAIN1,NPHP3,C24 KCTD12,NUP62CL,DZIP3,JAM3,HOXA9,ANKRD19,CDKN2A,BCAT1,OAT,LPHN2,CCDC82,HSD17B11,SAMHD1,WDR17,STK33,GSTP1,TRPC1,CKB,LIN28B,ALDH1L2,SACS,CL3,SACS03 VCAN,GPX8,GALNT13,PVRL3,MOXD1,HEY1,MAP7D3,ESD,MPP6,EYA4,SPG20,ZDBF2,ZNF204,IFT57,AKR1B1,ADAT2,ZNF717,CCDC88A,ZNF215,MIDI,FBN2,LOC1001, PLAGL1,PM20D2,LDHB,C150RF51,PTPN11,EPB41L2,TLE4,GOLM1,C60RF192,HOXD13,SLIT2,UCHL1,DYNC2H1,CPS1,GPR180,PYGL,NRN1,PRTFDC1,SLC16A1,DSC3,TMC1,TMC01,TMC1, HSPA4L,CDR1,PLS3,ECHDC1,SMARCA1,CXORF57,HOXD10和IRS4。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号